[8-K] Aura Biosciences, Inc. Reports Material Event

Rhea-AI Filing Summary

Aura Biosciences (AURA) furnished a press release announcing its financial results for the quarter ended June 30, 2025 and filed an updated corporate presentation as Exhibit 99.2. The press release is furnished and explicitly not deemed "filed" for purposes of Section 18 of the Exchange Act; the corporate presentation is filed for purposes of Section 18. The company identifies itself as an emerging growth company and notes its common stock trades on The Nasdaq Global Market.

The filing includes a broad cautionary statement of forward-looking items, covering R&D timing and costs, preclinical and clinical trials, manufacturing, third-party collaborations, commercialization, funding and regulatory approvals, market size, and an expected cash runway into the first half of 2027.

Positive

• Disclosed an expected cash runway into the first half of 2027
• Updated corporate presentation filed as Exhibit 99.2

Negative

• Filing emphasizes significant forward-looking risks including clinical trial uncertainty, funding sufficiency, regulatory approvals, and reliance on third-party collaborators

Insights

Securities Analyst

TL;DR Routine 8-K: quarterly results released and investor presentation updated; forward-looking risks and a cash runway are disclosed.

The filing is procedural but informative. Furnishing of a press release signals results are public and the separate filing of an updated corporate presentation provides investors with refreshed messaging and materials. The clear inclusion of forward-looking risks and an expected cash runway into the first half of 2027 gives investors explicit pointers on funding horizon and program risks without disclosing the underlying financial figures in this filing.

Corporate Governance / IR Specialist

TL;DR Communications-focused filing: disclosure, refreshed presentation, and standard forward-looking cautionary language.

From an investor relations perspective, furnishing the press release while filing the corporate deck is standard practice to update the market while limiting Section 18 liability for the release. The emerging growth company status is confirmed, and the broad forward-looking statement list helps manage expectations about clinical, regulatory, manufacturing, partnership and funding risks that could materially affect program timelines.

0001501796false00015017962025-08-132025-08-13

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 13, 2025

Aura Biosciences, Inc.

(Exact name of Registrant as Specified in Its Charter)

Delaware			001-40971	32-0271970
(State or Other Jurisdiction of Incorporation)			(Commission File Number)	(IRS Employer Identification No.)
80 Guest Street
Boston, Massachusetts				02135
(Address of Principal Executive Offices)				(Zip Code)

Registrant’s Telephone Number, Including Area Code: 617 500-8864

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, $0.00001 par value per share		AURA		The Nasdaq Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02 Results of Operations and Financial Condition.

On August 13, 2025, Aura Biosciences, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended June 30, 2025. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

The information in this Item 2.02, including Exhibit 99.1 hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Item 8.01 Other Events.

On August 13, 2025, the Company updated its corporate presentation for use in meetings with investors, analysts, and others. A copy of the corporate presentation is filed as Exhibit 99.2 for purposes of Section 18 of the Exchange Act.

Cautionary Note Regarding Forward Looking Statements

Statements contained under this Item 8.01 and in certain of the materials filed herewith regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements about the initiation, timing, progress, results, and cost of the Company’s research and development programs and the Company’s current and future preclinical studies and clinical trials, including statements regarding the timing of initiation and completion of studies or trials and related preparatory work, the period during which the results of the trials will become available, and the Company’s research and development programs; statements regarding the Company’s expectations for an improved quality of life of patients after treatment with bel-sar and changes to the treatment paradigm for patients; the Company’s ability to efficiently develop existing product candidates and discover new product candidates; the Company’s ability to successfully manufacture its drug substances and product candidates for preclinical use, for clinical trials and on a larger scale for commercial use, if approved; the ability and willingness of the Company’s third-party strategic collaborators to continue research and development activities relating to the Company’s development candidates and product candidates; the Company’s ability to commercialize its products, if approved; the Company’s ability to obtain funding for its operations necessary to complete further development and commercialization of its product candidates; the Company’s ability to obtain and maintain regulatory approval of its product candidates; statements regarding the Company’s beliefs and expectations for the high unmet medical need for an effective local treatment in ocular and urologic oncology to preserve organ function; the size and growth potential of the markets for the Company’s product candidates, and the Company’s ability to serve those markets; the Company’s financial performance; the Company’s expected cash runway into the first half of 2027; and the implementation of the Company’s business model, including strategic plans for its business and product candidates.

Any forward-looking statements are neither promises nor guarantees, and investors should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, many of which are beyond the Company’s control and which could cause actual results to differ materially from those expressed or implied by these forward-looking statements, including, without limitation, uncertainties inherent in clinical trials and in the availability and timing of data from ongoing clinical trials; the expected timing for submissions for regulatory approval or review by governmental authorities; the risk that the results of the Company’s preclinical and clinical trials may not be predictive of future results in connection with future clinical trials; the risk that interim data from ongoing clinical trials may not be predictive of final data from completed clinical trials; the risk that governmental authorities may disagree with the Company’s clinical trial designs even where the Company has obtained agreement with governmental authorities on the design of such trials, such as the Phase 3 Special Protocol agreement with the United States Food and Drug Administration; whether the Company will receive regulatory approvals to conduct trials or to market products; whether the Company’s cash resources will be sufficient to fund its foreseeable and unforeseeable operating expenses and capital expenditure requirements; the Company’s ongoing and planned preclinical activities; and the Company’s ability to initiate, enroll, conduct or complete ongoing and planned clinical trials. These risks, uncertainties, and other factors include those risks and uncertainties described under the heading “Risk Factors” in the Company’s most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q filed with the United States Securities and Exchange Commission (“SEC”) and in subsequent filings made by the Company with the SEC, which are available on the SEC’s website at www.sec.gov. Except as required by law, the Company disclaims any intention or responsibility for updating or revising any forward-looking statements contained under this Item 8.01 or in the materials filed herewith in the event of new information, future developments or otherwise. These forward-looking statements are based on the Company’s current expectations and speak only as of the date hereof and no representations or warranties (express or implied) are made about the accuracy of any such forward-looking statements.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.	Description
99.1	Press Release Dated August 13, 2025.
99.2	Corporate Presentation of the Company.
104	Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

			Aura Biosciences, Inc.
Date:	August 13, 2025	By:	/s/ Elisabet de los Pinos
			Elisabet de los Pinos  President and Chief Executive Officer (Principal Executive Officer)

FAQ

What did Aura Biosciences (AURA) disclose in this 8-K?

The company furnished a press release announcing financial results for the quarter ended June 30, 2025 and filed an updated corporate presentation as Exhibit 99.2.

Is the press release included in the 8-K considered "filed" with the SEC?

No. The 8-K states the press release is furnished and shall not be deemed "filed" for purposes of Section 18 of the Exchange Act.

Which exhibits were provided with the 8-K for AURA?

Exhibit 99.1 is the press release (furnished), Exhibit 99.2 is the corporate presentation (filed), and Exhibit 104 is the Cover Page Interactive Data File.

Does the filing state Aura's corporate status or exchange listing?

Yes. The company is identified as an emerging growth company and its common stock trades under the ticker AURA on The Nasdaq Global Market.

What forward-looking items does Aura highlight in the filing?

The filing lists forward-looking topics including R&D timing and cost, preclinical and clinical trials, manufacturing, collaborations, commercialization, funding, regulatory approval, market size, financial performance, and an expected cash runway into the first half of 2027.

Who signed the 8-K for Aura Biosciences?

The report is signed by Elisabet de los Pinos, President and Chief Executive Officer.